![]() Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | ![]() Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases. | ![]() Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. | |
Founding Date | Founding Date 2002 | Founding Date 2002 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations San Diego, US HQ | |
Employees | Employees 1,32324% increase | Employees 3217% decrease | Employees 2462% decrease |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 6.6 b | Valuation ($) 105.4 m |
Financial | |||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) $2.2m (FY, 2022) | Revenue (est.) N/A |
Net income | Net income ($440.2m) (FY, 2023) | Net income ($311.9m) (FY, 2022) | Net income ($30m) (FY, 2023) |
Operating ⚠ | |||
Patents Issued | Patents Issued N/A | Patents Issued 240 (FY, 2016) | Patents Issued 300 (FY, 2016) |
Funding | |||
Total funding raised | Total funding raised $ 1.5b | Total funding raised $ 468.9m | Total funding raised $ 10m |
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
View companyRegulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View company